- Email: [email protected]
DSM: Cargill cultures & enzymes
FOCUS manufacturing process based on a proprietary microorganism. The bacterium used is Basfia succiniciproducens, which produces succinic acid through natural processes. It is capable of metabolizing a variety of renewable feedstocks into succinic acid. The new process combines high efficiency with the use of renewable raw materials and the fixation of the greenhouse gas carbon dioxide in the production of succinic acid. This makes bio-based succinic acid an economically and ecologically attractive alternative to petrochemical raw materials. The demand for succinic acid is expected to grow strongly in the years ahead, driven mainly by bioplastics, chemical intermediates, solvents, polyurethanes, and plasticizers. BASF and CSM are currently modifying an existing fermentation facility at Purac’s Montmelo site near Barcelona, Spain, for the production of succinic acid. This plant will commence operations in late 2013 with an annual capacity of 10,000 tonne/y succinic acid. It will put the new jv company in a leading position in the global marketplace. This is complemented by plans for a second large-scale plant with an annual capacity of 50,000 tonne/y succinic acid to enable the company to respond to the expected increase in demand. The final investment decision for this plant will be made following a successful market introduction. Original Source: BASF SE, D-67056 Ludwigshafen, Germany, tel: +49 (0) 621 600, website: http://www.basf.com (5 Oct 2012) © BASF 2012. Original Source: Chemie Aktuell, 10 Oct 2012, (Website: http://www.maerkte-weltweit.de) (in German) © MBM Martin Brueckner Medien GmbH 2012. Original Source: NRW.INVEST (North RhineWestphalia), 29 Oct 2012, (2012-09), (NRW.INVEST GmbH, Economic Development Agency of the German State of North Rhine-Westphalia (NRW), Volklinger Strasse 4, 40219 Dusseldorf, Germany, tel: +49 (0)211 130 000, fax: +49 (0)211 130 00 154, website: http://www.nrwinvest-news.com) © NRW.INVEST GmbH 2012
Codexis cuts as Shell deal ends Biocatalysts specialist Codexis will slim down its 340-strong workforce by 133, by 30 Oct 2012, in line with costsavings efforts following Shell’s move to terminate a biofuels-related research agreement. Under a new deal, effective 31 Aug 2012, Shell surrendered all rights, excluding in Brazil, to use Codexis’ CodeXyme range of cellulase enzymes in
DECEMBER 2012
ON
C ATA LY S T S
biofuels, in exchange for royalty on net sales to other customers. About €5.9 M will be paid by Shell to cover FTE agreements and milestone payments for the early termination of the research agreement, which was due to end on 1 Nov 2012. This agreement, started in 2006, had been a main revenue stream for Codexis. In Brazil, Codexis is in talks with Raizen on the use of its enzymes in the production of second-generation ethanol. Shell can get preferential pricing on purchases of cellulase enzymes if a future supply agreement is reached. Despite a recent sales drop in this area, Codexis remains positive on the outlook of its pharmaceuticals business, due mainly to an expanded agreement to produce enzymes for Merck & Co until 2015. Codexis reported €18.0 M in revenues in 2Q 2012, down 12% year on year. Original Source: Speciality Chemicals, Sep 2012, 32 (9), 9 (Website: http://www.specchemonline.com/) © Quartz Business Media Ltd 2012
DSM: Cargill cultures & enzymes On 20 Sep 2012, DSM announced that it is in discussions with Cargill that may result in its acquisition of Cargill’s cultures and enzymes business. This business has sites in the US and France, about 200 employees, and net sales of about €45 M. The global market for these products is put at about €1 bn/y, with growth of about 5%/y. Original Source: Meuse-Rhine Journal, 30 Sep 2012, (287), (Wadsworth & Wadsworth Assoc, PO Box 42, NL-6245 ZG, Eijsden, The Netherlands, tel: +31 43 4093719, fax: +31 43 4098899, website: http://www.meuse-rhine-journal.com) © Stafford Wadsworth 2012. Original Source: Chimie Pharma Hebdo, 1 Oct 2012, (606), 8 (Website: http://www.industrie.com/chimie/) (in French) © ETAI Information 2012
DSM Pharmaceutical, Almac sign manufacturing agreement in biocatalysis DSM Pharmaceutical Products, has tied up with the Almac Group to provide sustainable manufacturing services to the pharmaceutical industry in the biocatalysis segment. The collaboration will use enzyme platform technologies, services and expertise for the manufacturing of active pharmaceutical ingredients. Almac will use its expertise in enzyme identification, scale-up and
implementation into early phase projects of the collaboration, while DSM Pharmaceutical will use its experience of over 30 commercial manufacturing bioprocesses run on a multi-tonne scale. Original Source: PBR Pharmaceutical Business Review, 8 Oct 2012, (Website: http://www.pharmaceutical-business-review.com/) © PBR 2012
Trials confirm DuPont enzymes offer sustainability benefits for cotton textile production DuPont Industrial Biosciences has presented results of collaborative trials with Pacific Textiles Ltd (Pacific Textiles), a Hong Kong-based manufacturer of custom fabrics, which demonstrate the significant sustainability benefits of bio-based enzymes used to replace traditional chemicals in cotton textile processing at bulk-scale production. DuPont’s enzymes are derived from natural resources and are biodegradable. DuPont PrimaGreen enzymes used in combination can eliminate the need for caustic chemicals, while also dramatically reducing water, energy use, and processing time. The trial with Pacific Textile confirmed the results from an earlier lab study DuPont conducted with Cotton Inc that was released in May 2012. Original Source: Dupont, DuPont Building, 1007, Market Street, Wilmington, DE 19898, USA, website: http://www.dupont.com (4 Oct 2012) © DuPont 2012
Fibria to produce cellulosic fuels with Ensyn’s technology in Brazil Fibria Celulose of Brazil and Ensyn of Canada have entered into an agreement to develop cellulosic liquid fuels and chemicals. Fibria Celulose will acquire a 6% stake Ensyn through an investment of about $20 M and retain an option to make further investments. Ensyn has developed the proprietary rapid thermal processing technology for converting wood and non-food biomass into renewable liquid fuels and chemicals. The transaction is likely to close by the end of Oct 2012. Fibria Celulose is a pulp and fibre producer. Ensyn is a biofuels company. Original Source: CTBR Clean Technology Business Review, 5 Oct 2012, (Website: http://www.cleantechnology-business-review.com/) © CTBR 2012
3
Codexis cuts as Shell deal ends Biocatalysts specialist Codexis will slim down its 340-strong workforce by 133, by 30 Oct 2012, in line with costsavings efforts following Shell’s move to terminate a biofuels-related research agreement. Under a new deal, effective 31 Aug 2012, Shell surrendered all rights, excluding in Brazil, to use Codexis’ CodeXyme range of cellulase enzymes in
DECEMBER 2012
ON
C ATA LY S T S
biofuels, in exchange for royalty on net sales to other customers. About €5.9 M will be paid by Shell to cover FTE agreements and milestone payments for the early termination of the research agreement, which was due to end on 1 Nov 2012. This agreement, started in 2006, had been a main revenue stream for Codexis. In Brazil, Codexis is in talks with Raizen on the use of its enzymes in the production of second-generation ethanol. Shell can get preferential pricing on purchases of cellulase enzymes if a future supply agreement is reached. Despite a recent sales drop in this area, Codexis remains positive on the outlook of its pharmaceuticals business, due mainly to an expanded agreement to produce enzymes for Merck & Co until 2015. Codexis reported €18.0 M in revenues in 2Q 2012, down 12% year on year. Original Source: Speciality Chemicals, Sep 2012, 32 (9), 9 (Website: http://www.specchemonline.com/) © Quartz Business Media Ltd 2012
DSM: Cargill cultures & enzymes On 20 Sep 2012, DSM announced that it is in discussions with Cargill that may result in its acquisition of Cargill’s cultures and enzymes business. This business has sites in the US and France, about 200 employees, and net sales of about €45 M. The global market for these products is put at about €1 bn/y, with growth of about 5%/y. Original Source: Meuse-Rhine Journal, 30 Sep 2012, (287), (Wadsworth & Wadsworth Assoc, PO Box 42, NL-6245 ZG, Eijsden, The Netherlands, tel: +31 43 4093719, fax: +31 43 4098899, website: http://www.meuse-rhine-journal.com) © Stafford Wadsworth 2012. Original Source: Chimie Pharma Hebdo, 1 Oct 2012, (606), 8 (Website: http://www.industrie.com/chimie/) (in French) © ETAI Information 2012
DSM Pharmaceutical, Almac sign manufacturing agreement in biocatalysis DSM Pharmaceutical Products, has tied up with the Almac Group to provide sustainable manufacturing services to the pharmaceutical industry in the biocatalysis segment. The collaboration will use enzyme platform technologies, services and expertise for the manufacturing of active pharmaceutical ingredients. Almac will use its expertise in enzyme identification, scale-up and
implementation into early phase projects of the collaboration, while DSM Pharmaceutical will use its experience of over 30 commercial manufacturing bioprocesses run on a multi-tonne scale. Original Source: PBR Pharmaceutical Business Review, 8 Oct 2012, (Website: http://www.pharmaceutical-business-review.com/) © PBR 2012
Trials confirm DuPont enzymes offer sustainability benefits for cotton textile production DuPont Industrial Biosciences has presented results of collaborative trials with Pacific Textiles Ltd (Pacific Textiles), a Hong Kong-based manufacturer of custom fabrics, which demonstrate the significant sustainability benefits of bio-based enzymes used to replace traditional chemicals in cotton textile processing at bulk-scale production. DuPont’s enzymes are derived from natural resources and are biodegradable. DuPont PrimaGreen enzymes used in combination can eliminate the need for caustic chemicals, while also dramatically reducing water, energy use, and processing time. The trial with Pacific Textile confirmed the results from an earlier lab study DuPont conducted with Cotton Inc that was released in May 2012. Original Source: Dupont, DuPont Building, 1007, Market Street, Wilmington, DE 19898, USA, website: http://www.dupont.com (4 Oct 2012) © DuPont 2012
Fibria to produce cellulosic fuels with Ensyn’s technology in Brazil Fibria Celulose of Brazil and Ensyn of Canada have entered into an agreement to develop cellulosic liquid fuels and chemicals. Fibria Celulose will acquire a 6% stake Ensyn through an investment of about $20 M and retain an option to make further investments. Ensyn has developed the proprietary rapid thermal processing technology for converting wood and non-food biomass into renewable liquid fuels and chemicals. The transaction is likely to close by the end of Oct 2012. Fibria Celulose is a pulp and fibre producer. Ensyn is a biofuels company. Original Source: CTBR Clean Technology Business Review, 5 Oct 2012, (Website: http://www.cleantechnology-business-review.com/) © CTBR 2012
3